- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | NLS Pharmaceutics stock tumbles after merger approval with Kadimastem | 3 | Investing.com | ||
| 30.09. | NLS Pharmaceutics: Aktie bricht nach Fusionszustimmung mit Kadimastem ein | 1 | Investing.com Deutsch | ||
| 30.09. | Aktionäre von NLS Pharmaceutics stimmen Fusion mit Kadimastem zu | 2 | Investing.com Deutsch | ||
| 30.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.09. | NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting | 435 | PR Newswire | Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH, Sept. 30, 2025 /PRNewswire/... ► Artikel lesen | |
| 25.09. | NLS Pharmaceutics files to sell 5M common shares for holders | 2 | Seeking Alpha | ||
| 25.09. | NLS Pharmaceutics Ltd. - F-1, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 19.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Fusion von NLS Pharmaceutics und Kadimastem: SEC erteilt Freigabe | 4 | Investing.com Deutsch | ||
| 10.09. | SEC clears registration for NLS Pharmaceutics and Kadimastem merger | 1 | Investing.com | ||
| 10.09. | Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger | 99 | PR Newswire | ZURICH and NESS ZIONA, Israel, Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous... ► Artikel lesen | |
| 04.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 04.09. | NLS Pharmaceutics merger partner Kadimastem secures Hong Kong patent for diabetes therapy | 1 | Investing.com | ||
| 25.08. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 06.08. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 17.07. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.06. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders | 998 | PR Newswire | ZURICH, June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 06.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,080 | 0,00 % | What's Going On With Recursion Pharmaceuticals Stock On Wednesday? | ||
| QIAGEN | 40,765 | +1,52 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| IMMUNOVANT | 16,075 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 56,29 | -0,97 % | Stifel bestätigt Kaufempfehlung für Kymera Therapeutics vor wichtigen Studiendaten | ||
| ARCUTIS BIOTHERAPEUTICS | 21,240 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,485 | -0,44 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| DISC MEDICINE | 70,28 | +3,52 % | Mona Ashiya verlässt Verwaltungsrat von Disc Medicine - Gremium auf acht Mitglieder verkleinert | ||
| ARVINAS | 9,750 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,200 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,480 | -0,15 % | BofA Securities hebt Kursziel für Amylyx-Aktie auf 16 US-Dollar an | ||
| STRUCTURE THERAPEUTICS | 28,450 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| LENZ THERAPEUTICS | 48,600 | 0,00 % | Lenz Therapeutics platziert Aktienpaket im Wert von 80 Millionen US-Dollar | ||
| XENETIC BIOSCIENCES | 10,370 | 0,00 % | Xenetic Biosciences Stock Surges 123% | ||
| PRIME MEDICINE | 6,450 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,350 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen |
Das Unternehmen NLS PHARMACEUTICS LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NLS PHARMACEUTICS LTD finden Sie auf Wallstreet Online.